Biogen Idec, formed by the merger of Biogen and IDEC Pharmaceuticals in 2003, is headquartered in Cambridge, MA, and is a global biotechnology company with products and capabilities in oncology, neurology and immunology.

The company's leading products are.

Avonex (interferon beta 1a). Avonex is a therapy for relapsed and remitting forms of multiple sclerosis, to decrease the number of flare-ups and slow the occurrence of some of the physical disability common in people with multiple sclerosis.

Tysabri (natalizumab). Tysabri is a monoclonal antibody, for the treatment of certain patients with relapsing forms of multiple sclerosis.

Zevalin (Ibritumomab Tiuxetan). Zevalin is used in treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with Rituximab-refractory follicular NHL.

*Information above taken from materials provided by Biogen Idec.